Follow-The-Filings

Security

BCAX

Bicara Therapeutics Inc. · COM

Equity holders as of 2026 Q1 (each manager’s latest book)

8 owners 2 new max 0.0% (Ken Griffin - Citadel Adv...)

grid → activity →
owners 8
max % 0.0%
tracked value $81M
qoq N 2 A 2 R 2

holders

sorted by % of portfolio · long equity only

manager % port activity shares value history
Ken Griffin - Citadel Advisors LLC 2026 Q1 0.0% Add 0.00 pp 1,659,342 $33M hist
Vanguard Group Inc. 2025 Q4 stale 0.0% Reduce 0.00 pp 2,186,150 $37M hist
D. E. Shaw & Co., Inc. 2026 Q1 0.0% Add 0.00 pp 276,943 $6M hist
Israel Englander - Millennium Management LLC 2026 Q1 0.0% Reduce 0.00 pp 156,702 $3M hist
Two Sigma Investments, LP 2025 Q4 stale 0.0% Exit 0.00 pp 98,481 $2M hist
Norges Bank 2025 Q4 stale 0.0% Exit 0.00 pp 42,889 $722 hist
Dmitry Balyasny - Balyasny Asset Management L.P. 2026 Q1 0.0% New 0.0% 21,797 $434 hist
Cliff Asness - Aqr Capital Management LLC 2026 Q1 0.0% New 0.0% 13,186 $262 hist

8 current · options excluded

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2024 FY2025
Revenue — —
Gross profit — —
Gross margin — —
Net income -$68M -$137.95M
Net margin — —

Balance sheet

Metric FY2024 FY2025
Total current assets $502.53M $422.05M
Total non-current assets * $7.46M $8.94M
Total assets $510M $430.99M
Total current liabilities $17.99M $28.95M
Total non-current liabilities * $131,000 $593,000
Total equity $491.88M $401.45M

Cash flow

Metric FY2024 FY2025
Cash from operations -$74.75M -$106.83M
Cash from investing -$9,000 -$318.45M
Cash from financing $334.03M $32.26M
Net change in cash $259.27M -$393.03M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

ownership over time

filing count by report period · click a bar for that quarter’s holders